Although the data in this study focused on lung adenocarcinoma and cervical adenocarcinoma, the observed overexpression of RBBP4 in clinical specimens of gastric cancer, colorectal cancer, and esophageal cancer (data not shown) suggests that RBBP4 may similarly contribute to cisplatin resistance in these cancers. Here, RBBP4 is linked to cancer.